SEARCH

SEARCH BY CITATION

References

  • 1
    United Nations World Tourism Organization. Historical perspective of world tourism: international tourist arrivals, 1950–2005. Available at: http://www.unwto.org/facts/eng/historical.htm. (Accessed 2009 Jan 2).
  • 2
    Chen LH, Wilson ME. The role of the traveler in emerging infections and magnitude of travel. Med Clin North Am 2008; 92:14091432.
  • 3
    Dupont HL, Steffen R. Textbook of travel medicine and health. Hamilton, UK: BC Decker Inc., 2001.
  • 4
    Ericsson CD. Travellers with pre-existing medical conditions. Int J Antimicrob Agents 2003; 21:181188.
  • 5
    World Health Organization. International travel and health. Geneva, Switzerland: WHO, 2008.
  • 6
    McCarthy AE, Mileno MD. Prevention and treatment of travel-related infections in compromised hosts. Curr Opin Infect Dis 2006; 19:450455.
  • 7
    Landelijk coördinatiecentrum reizigersadvisering. Na- tional Coordination Centre for Traveler's Health Advice. National guideline on traveler's diarrhea. Amsterdam, The Netherlands: LCR, 2007.
  • 8
    National Travel Health Network and Centre NaTHNaC. Travellers with pre-existing medical conditions. Available at: www.nathnac.org. (Accessed 2008 Dec 14).
  • 9
    Committee to Advise on Tropical Medicine and Travel (CATMAT). The immunocompromised traveller. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007; 33(ACS-4):124.
  • 10
    Kovarik JM, Burtin P. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin Emerg Drugs 2003; 8:4762.
  • 11
    Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 2010; 9:A288A292.
  • 12
    Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126:15041517.
  • 13
    World Health Organization. Global distribution of hepatitis A, B and C, 2001. Wkly Epidemiol Rec 2002; 77:45.
  • 14
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2010. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2009.
  • 15
    Landelijk coördinatiecentrum reizigersadvisering. Na- tional Coordination Centre for Traveller's Health Advice. National guideline for non-HIV-related immunosuppressive disorders. Amsterdam, The Netherlands: LCR, 2006.
  • 16
    Spiegelhalter DJ, Thomas A, Best NG. WinBUGS version 1.2 user manual. Cambridge, UK: MRC Biostatistics Unit, 1999.
  • 17
    Gilks WR, Richardson S, Spiegelhalter DJ. Markov chain Monte Carlo in practice. London, UK: Chapman & Hall, 1996.
  • 18
    Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 80:2738.
  • 19
    R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available at: http://www.R-project.org. (Accessed 2010 Sep 1).
  • 20
    Kosmidis I. Brglm: bias reduction in binary-response GLMs. Available at: http://go.warwick.ac.uk/kosmidis/software. (Accessed 2010 Sep 4).
  • 21
    Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:34033412.
  • 22
    Woolacott NF, Khadjesari ZC, Bruce IN, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2006; 24: 587593.
  • 23
    Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:22872293.
  • 24
    Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007; 66:308312.
  • 25
    Rack J, Wichmann O, Kamara B, et al. Risk and spectrum of diseases in travelers to popular tourist destinations. J Travel Med 2005; 12:248253.
  • 26
    Redman CA, Maclennan A, Wilson E, Walker E. Diarrhea and respiratory symptoms among travelers to Asia, Africa, and South and Central America from Scotland. J Travel Med 2006; 13:203211.
  • 27
    Cobelens FG, Leentvaar-Kuijpers A, Kleijnen J, Coutinho RA. Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. Trop Med Int Health 1998; 3:896903.
  • 28
    Pitzurra R, Steffen R, Tschopp A, Mutsch M. Diarrhoea in a large prospective cohort of European travellers to resource-limited destinations. BMC Infect Dis 2010; 10:231.
  • 29
    Van Herck K, Van Damme P, Castelli F, et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med 2004; 11:38.
  • 30
    United States Office of Travel and Tourism Industries. United States Travel and Tourism Statistics: 2008 US Resident Outbound, June 2009. Available at: http://tinet.ita.doc.gov. (Accessed 2009 Jul 4).
  • 31
    Lim E, Koh WH, Loh SF, et al. Non-thyphoidal salmonellosis in patients with systemic lupus erythematosus. A study of fifty patients and a review of the literature. Lupus 2001; 10:8792.
  • 32
    Dhar JM, al-Khader AA, al-Sulaiman M, al-Hasani MK. Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. Q J Med 1991; 78:235250.
  • 33
    Espelage W, an der Heiden M, Stark K, Alpers K. Characteristics and risk factors for symptomatic Giardia lamblia infections in Germany. BMC Public Health 2010; 10:41.
  • 34
    Epple HJ. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis 2009; 27:555559.